Skip to main content

Advertisement

Log in

Selective α1-adrenoceptor antagonist (controlled release tablets) in preoperative management of pheochromocytoma

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

The objective of this article is to evaluate the efficacy of Doxazosin Mesylate Controlled Release Tablets for preoperative treatment of patients with pheochromocytoma. Between 2003 and 2008, 67 patients with confirmed diagnoses of pheochromocytoma were enrolled in this study. According to the drug used in preoperative management, patients were divided into two groups: Doxazosin Mesylate pretreatment group (n = 36) and Phenoxybenzamine pretreatment group (n = 31). Surgery was performed only in patients who met the optimal preoperative condition. The hematocrit decreased significantly (P < 0.001) after antiadrenergic therapy in patients pretreated with phenoxybenzamine or doxazosin. There was no significant difference between the fluid intakes during operation in both groups. The systolic arterial pressures both before and after induction of anesthesia were all significantly higher in the doxazosin patients than in the phenoxybenzamine group (P < 0.05). After tumor removed, the lowest systolic arterial pressure was significantly higher in doxazosin group than in phenoxybenzamine group (P < 0.05). The fluctuation of systolic arterial pressure during operation was more stable in doxazosin group than in phenoxybenzamine group (P < 0.05). Doxazosin mesylate controlled release tablet was as effective as phenoxybenzamine in preoperative volume expansion. Although phenoxybenzamine provided better arterial pressure control, patients pretreated with DOX experienced more stable perioperative hemodynamic changes, shorter preoperative management periods and more simple medication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. J.W. Lenders, G. Eisenhofer, M. Mannelli, K. Pacak, Pheochromocytoma. Lancet 366(9486), 665–675 (2005)

    Article  PubMed  Google Scholar 

  2. K. Pacak, G. Eisenhofer, H. Ahlman, S.R. Bornstein, A.P. Gimenez-Roqueplo, A.B. Grossman et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat. Clin. Pract. Endocrinal. Metab. 3(2), 92–102 (2007)

    Google Scholar 

  3. M. Brown, Pheochromocytoma, in Oxford Textbook of Medicine, 3rd edn., ed. by D.J. Weatherall, J.G.G. Ledingham, D.A. Warrell (Oxford University Press, Oxford, 1996), pp. 2553–2557

    Google Scholar 

  4. D.L. Bogdonoff, Pheochromocytoma: specialist cases that all must be prepared to treat? Cardiothorac. Vasc. Anesth. 16(3), 267–269 (2002)

    Article  Google Scholar 

  5. Y. Miura, Yoshinaga.K. Doxazosin, A newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma. Am. Heart J. 116(6pt2), 1785–1789 (1988)

    Article  CAS  PubMed  Google Scholar 

  6. C. Prys-Roberts, J.R. Farndon, Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J. Surg. 26(8), 1037–1042 (2002)

    Article  PubMed  Google Scholar 

  7. D.L. Pan, H.Z. Li, Z.P. Zeng, The discussion of standards for clinical functional gradation and preoperative preparation of pheochromocytoma. Chin. J. Surg. 42(18), 1089–1092 (2004)

    PubMed  Google Scholar 

  8. Y. Zhu, W.Q. Wang, Y.X. Wu, C.Y. Zhang, W.B. Rui, W.L. Zhou et al., Application of doxazosin controlled-release tablets in the pre-operative management of patients with pheochromocytoma: a pilot study. J. Mod. Urol. 12, 83–84 (2007)

    Google Scholar 

  9. S.Z. Langer, Presynaptic regulation of the release of catecholamines. Pharmacol. Rev. 32(7), 337–362 (1981)

    Google Scholar 

  10. L.X. Cubeddu, N.A. Zarate, C.B. Rosales, D.W. Zschaeck, Prazosin and propranolol in preoperative management of pheochromocytoma. Clin. Pharmacol. Ther. 32(2), 156–160 (1982)

    Article  CAS  PubMed  Google Scholar 

  11. V.A. Alabaster, M.J. Davey, The alpha 1-adrenoceptor antagonist profile of doxazosin: preclinical pharmacology. Br. J. Clin. Pharmacol. 21(Suppl. 1), 9S–17S (1986)

    CAS  PubMed  Google Scholar 

  12. H.L. Elliott, P.A. Meredith, J. Vincent, J.L. Reid, Clinical pharmacological studies with doxazosin. Br. J. Clin. Pharmacol. 21(Suppl. 1), 27S–31S (1986)

    CAS  PubMed  Google Scholar 

  13. A.N. van der Horst-Schrivers, M.N. Kerstens, B.H. Wolffenbuttel, Preoperative pharmacological management of phaeochromcytoma. Neth. J. Med. 64(8), 290–295 (2006)

    PubMed  Google Scholar 

  14. M. Brauckhoff, O. Gimm, H. Dralle, Preoperative and surgical therapy in sporadic and familial pheochromocytoma. Front Horm Res. 31, 121–144 (2004)

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Shanghai Municipal Natural Science Foundation (No. 09ZR1418500), grant from the Science and Technology Commission of Shanghai Municipality.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yu Zhu.

Additional information

Hong-chao He is listed as co-first author.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhu, Y., He, Hc., Su, Tw. et al. Selective α1-adrenoceptor antagonist (controlled release tablets) in preoperative management of pheochromocytoma. Endocr 38, 254–259 (2010). https://doi.org/10.1007/s12020-010-9381-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-010-9381-x

Keywords

Navigation